CUMBERLAND PHARMACEUTICALS APPOINTS MARTIN BROWN JR. TO ITS BOARD OF DIRECTORS

Rhea-AI Summary

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced the appointment of Martin Brown Jr. to its Board of Directors as of July 19, 2022. Brown, with nearly 30 years of legal experience, previously served on the Board of Brown-Forman Corporation and currently practices at Adams and Reese LLP. His background in health care and corporate law is expected to enhance Cumberland's mission to address unmet medical needs. Brown holds degrees from Yale University and Vanderbilt University.

Positive

• Martin Brown Jr. brings extensive legal and health care experience to the board, potentially enhancing strategic decisions.
• Brown's previous tenure on the board of Brown-Forman Corporation could provide valuable insights into corporate governance and management.

Negative

• None.

NASHVILLE, Tenn., July 19, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that Martin Brown Jr. has joined the company's Board of Directors.

Brown previously served for 10 years on the Board of directors of Brown-Forman Corporation, a large American wine and spirits company listed on the New York Stock Exchange. The brands in Brown-Forman's portfolio include Jack Daniel's and Woodford Reserve whiskeys, Benriach scotch, Herradura tequila and Finlandia vodka. 

Brown is an attorney at Adams and Reese LLP, a multi-disciplinary law firm with over 270 attorneys and advisors located throughout the United States. He has nearly 30 years of legal experience representing privately held businesses, counseling owners in complex business transactions, intellectual property licensing, international commerce, mergers and acquisitions, and estate planning. He has been listed since 2009 in the corporate law category of in Best Lawyers^®.

Additionally, he has served since 2018 on the board of directors of the parent company of Aegis Sciences Corporation, a federally certified health care laboratory headquartered in Nashville.

Brown has been an active board member for many community organizations, including the Land Trust for Tennessee, Nashville Public Radio, Montgomery Bell Academy, Nashville Public Television, Centerstone Mental Health Center, Cheekwood Estate and Gardens, and Tennessee chapter of the Nature Conservancy.

"Martin brings tremendous legal, health care and civic experience to Cumberland's Board of Directors," said A.J. Kazimi, Cumberland Pharmaceuticals CEO and Board Chairman. "We are honored to welcome him to our board and know his contributions will be valuable in supporting our mission to deliver innovative products that address poorly met medical needs."

Brown earned his bachelor's degree from Yale University and his juris doctor from Vanderbilt University.

Cumberland's Board of Directors also includes Kazimi; Dr. Gordon R. Bernard, executive vice president for research at Vanderbilt University Medical Center; Joey A. Jacobs, former Chairman and CEO of Acadia Healthcare; James R. Jones, former managing partner at KPMG; Caroline R. Young, former CEO of the Nashville Health Care Council and current vice president of partnership development at Frist Cressey Ventures; Kenneth J. Krogulski, managing partner and chief investment officer at Berkshire Asset Management; and Joseph C. Galante, a music industry executive and former Chairman of Sony Music Nashville and RCA Nashville.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the delivery of high-quality, prescription brands designed to improve patient care. The company develops, acquires, and commercializes products for the hospital acute care, gastroenterology, rheumatology and oncology market segments. The company's portfolio includes eight FDA-approved brands.

The company also has a series of Phase II clinical programs underway evaluating its ifetroban product candidate in patients with cardiomyopathy associated with Duchenne Muscular Dystrophy (DMD), Systemic Sclerosis (SSc), and Aspirin-Exacerbated Respiratory Disease (AERD). More information can be found on the company's website at www.cumberlandpharma.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-appoints-martin-brown-jr-to-its-board-of-directors-301588401.html

SOURCE Cumberland Pharmaceuticals Inc.

FAQ

Who is Martin Brown Jr. and what is his role at Cumberland Pharmaceuticals?

Martin Brown Jr. is a new member of the Board of Directors at Cumberland Pharmaceuticals, appointed on July 19, 2022.

What experience does Martin Brown Jr. bring to Cumberland Pharmaceuticals?

Brown has nearly 30 years of legal experience and previously served on the Board of Brown-Forman Corporation.

What is the significance of Martin Brown Jr.'s appointment for CPIX investors?

His appointment could lead to improved governance and strategic decisions, potentially benefiting investors.

When was Martin Brown Jr. appointed to the Board of Directors of Cumberland Pharmaceuticals?

He was appointed on July 19, 2022.

What is Cumberland Pharmaceuticals known for?

Cumberland Pharmaceuticals is a specialty pharmaceutical company focused on developing prescription brands for various medical fields.